H1 2022 marked by the start of recruitment for the phase 2b study with AEF0117 for the treatment of cannabis addiction Solid cash position at €39.8 million as of June 30, 2022, including the
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal - read this article along with other careers information, tips and advice on BioSpace
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BioXcel Therapeutics (BTAI) Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.